Vivere Pharmaceutica - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 692,002 | 775,761 | 936,078 | 666,688 | 543,887 | 403,023 | 111,574 | 94,441 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 75,461 | 87,004 | 103,610 | 55,343 | 25,571 | 43,695 | 14,183 | 11,966 |
| Equity | 115,829 | 166,127 | 193,266 | 180,374 | 175,357 | 100,229 | 114,412 | 126,377 |
| Liabilities | 49,665 | 95,813 | 53,955 | 49,254 | 77,994 | 13,225 | 2,545 | 1,586 |
| Non-current assets | 2,839 | 11,905 | 4,605 | 6,455 | 14,738 | 10,083 | 302 | 0 |
| Current assets | 162,655 | 250,035 | 241,960 | 222,411 | 238,379 | 101,886 | 116,655 | 127,963 |
| Total assets | 165,494 | 261,940 | 246,565 | 228,866 | 253,117 | 111,969 | 116,957 | 127,963 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 7,365 | 19,758 | 18,304 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -16.3% | +12.1% | +20.7% | -28.8% | -18.4% | -25.9% | -72.3% | -15.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 45.6% | 33.2% | 42.0% | 24.2% | 10.1% | 39.0% | 12.1% | 9.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 65.1% | 52.4% | 53.6% | 30.7% | 14.6% | 43.6% | 12.4% | 9.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 10.9% | 11.2% | 11.1% | 8.3% | 4.7% | 10.8% | 12.7% | 12.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.6 | 0.3 | 0.3 | 0.4 | 0.1 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 346,001 | 387,881 | 468,039 | 333,344 | 271,944 | 166,766 | 37,191 | 31,480 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vivere Pharmaceutica - Social security debts
The amount of overdue SODRA debt for the company Vivere Pharmaceutica as of the last working day is: 1 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-15 | 0.64 |
| 2026-08-26 | 2026-09-02 | 0.64 |
| 2026-08-23 | 2026-08-23 | 0.64 |
| 2026-08-19 | 2026-08-19 | 0.64 |
| 2026-08-16 | 2026-08-17 | 0.64 |
| 2026-07-19 | 2026-08-14 | 0.64 |
| 2026-07-16 | 2026-07-17 | 0.64 |
| 2026-06-16 | 2026-07-14 | 0.64 |
| 2026-05-17 | 2026-06-07 | 0.64 |
| 2026-05-03 | 2026-05-14 | 0.64 |
| 2026-04-20 | 2026-04-29 | 0.64 |
| 2026-03-29 | 2026-04-14 | 0.64 |
| 2026-03-17 | 2026-03-27 | 0.64 |
| 2026-02-18 | 2026-03-11 | 0.64 |
| 2026-01-22 | 2026-02-16 | 0.64 |
| 2026-01-16 | 2026-01-21 | 0.37 |
| 2026-01-01 | 2026-01-14 | 0.37 |
| 2025-12-28 | 2025-12-30 | 0.37 |
| 2025-12-16 | 2025-12-27 | 86.31 |
| 2025-11-18 | 2025-12-15 | 0.37 |
| 2025-10-23 | 2025-11-16 | 0.37 |
| 2025-07-24 | 2025-07-31 | 81.00 |
| 2025-07-16 | 2025-07-23 | 80.85 |
| 2025-04-16 | 2025-04-21 | 80.85 |
| 2023-08-17 | 2023-08-24 | 0.78 |
| 2023-07-28 | 2023-08-15 | 0.78 |
| 2023-07-24 | 2023-07-25 | 0.80 |
| 2023-06-16 | 2023-06-22 | 335.28 |
| 2023-05-16 | 2023-05-18 | 0.70 |
| 2023-05-02 | 2023-05-14 | 0.70 |
| 2023-04-26 | 2023-04-28 | 0.70 |
| 2023-02-17 | 2023-02-21 | 331.52 |
| 2023-02-06 | 2023-02-16 | 0.23 |
| 2023-01-24 | 2023-02-03 | 0.23 |
| 2023-01-20 | 2023-01-22 | 0.23 |
| 2022-10-18 | 2022-10-20 | 326.74 |
| 2022-07-25 | 2022-08-22 | 0.36 |
| 2022-02-17 | 2022-03-13 | 0.29 |
| 2022-01-31 | 2022-02-14 | 0.29 |
Vivere Pharmaceutica - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vivere Pharmaceutica, UAB (code 302748312) is a private limited liability company engaged in wholesale of pharmaceutical and medical goods. In 2025, it generated €94.4K in revenue and €12.0K in net profit, corresponding to a profit margin of 12.7%. Revenue declined by 15.4% year on year and by 76.6% over two years, compared with €403.0K in 2023. Net profit also decreased from €43.7K in 2023 to €14.2K in 2024 and €12.0K in 2025, while profitability remained relatively stable. The balance sheet is conservative: total assets were €128.0K, equity €126.4K and liabilities only €1.6K in 2025. This results in an equity ratio of 98.8% and a debt-to-equity ratio of 0.01, indicating very low leverage. Return on equity was 9.5% and return on assets 9.3%, while asset turnover stood at 0.74x. Revenue per employee was €31.5K and profit per employee €4.0K, pointing to modest but positive operating efficiency.